Nasus Pharma, Ltd. - Volume dana dhuwit perusahaan NSRX

Simbol resmi perusahaan Nasus Pharma Ltd (NSRX)

The cash reserves of Nasus Pharma Ltd (NSRX), as reported by the GURU.Markets system, correlate with the scaling of nasal technologies for allergy treatment. The latest parameter stands at 0.00, although the risk of failed tests and patent disputes could destabilize the capital. Meanwhile, proprietary protection against price wars in the intranasal systems niche supports the current liquidity of the company.

NSRX - Volume dana dhuwit perusahaan nasuspharma.com ing rentang 14.08.2025 - 21.11.2026

Rincian metrik lan analitis perusahaan Nasus Pharma Ltd (NSRX)

- nilai saham lan prakiraan konsensus rega:
Analisis komprehensif perusahaan:Nasus Pharma Ltd NSRX
Produk mawa merek Nasus Pharma, Ltd.

Developing innovative intranasal drug delivery systems requires significant capital expenditures in R&D and certification. Analyzing the cash balance allows for tracking the burn rate of liquid reserves without reporting time lags, which determines the ability of Nasus Pharma Ltd (NSRX) to cover its obligations independently. A stable cash reserve guarantees financial stability, although excess liquidity may signal inefficient capital allocation.